Comprehensive characterization of these novel targets is a clear next step in understanding their clinical utility in frontline‐treatment selection for patients with BRAF‐mutant melanoma, as biomarkers of treatment resistance, and their diagnostic potential. The gene discussed is BRAF; the disease is melanoma.